Summary
The supplied “claims” are general patent/market-protection statements and do not map to FDA-approved prescribing information content for ZOLGENSMA. No on-label prescribing, dosing, contraindications, warnings/precautions, interactions, adverse reactions, or administration claims were evaluated against the provided label excerpts.
Category Scores
Accurate Statements
Zolgensma is marketed as a one-time gene therapy for spinal muscular atrophy (SMA).
Not supported by the provided label excerpts; no label text provided that states “one-time,” “marketed as,” or directly matches this phrasing to Sections 1/2/etc. in the excerpt set.
Unsupported Statements
Zolgensma is marketed as a one-time gene therapy for spinal muscular atrophy (SMA).
The provided label excerpts include liver injury/monitoring and corticosteroid prophylaxis/tapering, but do not include label language supporting the specific “marketed as a one-time gene therapy” phrasing. SMA indication text is not provided in the excerpts.
Patent expiration depends on the filing date, any patent term adjustments, and the specific country’s rules.
Not a claim that appears in, or is supported by, the provided prescribing information excerpts.
For gene therapies like Zolgensma, overlapping layers of patents (vector, genetic payload, manufacturing/process, and use claims) can extend market protection even when some earlier patents reach their base term.
Not present in, or supported by, the provided prescribing information excerpts.
DrugPatentWatch.com is commonly used to check the expiration or remaining life of specific patents and to see which patents are still active.
Not present in, or supported by, the provided prescribing information excerpts.
For gene therapies, biosimilar-style logic may not map cleanly to conventional biologics because the products are highly process- and construct-specific.
Not present in, or supported by, the provided prescribing information excerpts.
Competitors can challenge patent coverage by arguing non-infringement, invalidity, or by designing around specific claims.
Not present in, or supported by, the provided prescribing information excerpts.
Competitors may design around specific claims by changing vector components, manufacturing steps, or payload design.
Not present in, or supported by, the provided prescribing information excerpts.
Contradictions
Important Omissions
No audit-relevant on-label prescribing information was provided or evaluated regarding the requested FDA label alignment (e.g., dosing/administration specifics, contraindications, boxed warnings, warnings/precautions, drug interactions, adverse reactions, or monitoring).
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The submitted claims are about patent/market protection and do not include direct prescribing, dosing, safety, or administration instructions that could be judged as conflicting with the label. However, the audit cannot verify on-label correctness because the claim content is not prescribing-information content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
The provided “AI response” claims are largely unrelated to FDA-approved prescribing information and do not include auditable label-based prescribing content. Only one partially relevant claim (“one-time gene therapy” for SMA) is not supported by the provided label excerpts.
Suggested Improvement
Evaluate only claims that are directly about FDA label content (e.g., indication text, dosing/administration, contraindications, boxed warnings, warnings/precautions, interactions, adverse reactions, and monitoring). Provide the exact label-mapped claim wording and ensure the corresponding label sections (e.g., Section 1 indication and Section 2 dosing details) are included in the excerpts.